PCM
CYTK icon

Penserra Capital Management’s Cytokinetics CYTK Stock Holding History

Penserra Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,910
Closed -$68K – 1409
2021
Q3 		$68K Buy
1,910
+275
+17% +$8.1K ﹤0.01% 958
2021
Q2 		$32K Buy
1,635
+30
+2% +$704 ﹤0.01% 1085
2021
Q1 		$37K Sell
1,605
-20
-1% -$427 ﹤0.01% 868
2020
Q4 		$33K Buy
1,625
+1,021
+169% +$18.7K ﹤0.01% 755
2020
Q3 		$13K Buy
+604
New +$14.1K ﹤0.01% 791

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Penserra Capital Management's CYTK Position: Q4 2021 in Review

Penserra Capital Management sold out of Cytokinetics (CYTK) in Q4 2021, closing a stake of 1,910 shares — an estimated $68K sold.

Penserra Capital Management first reported a position in CYTK in Q3 2020 and held it in 5 quarters. The position peaked at $68K in Q3 2021. 250 funds tracked by Wall St. Rank hold CYTK as of Q4 2021.

  • Penserra Capital Management reported no remaining Cytokinetics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,910 Cytokinetics shares in Q4 2021, an estimated $68K.
  • Penserra Capital Management first reported a position in Cytokinetics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Cytokinetics position peaked at $68K in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.